Deltec Asset Management LLC Sells 400 Shares of Abbott Laboratories (NYSE:ABT)

Deltec Asset Management LLC decreased its stake in shares of Abbott Laboratories (NYSE:ABT) by 0.3% during the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 159,300 shares of the healthcare product maker’s stock after selling 400 shares during the quarter. Abbott Laboratories comprises 1.6% of Deltec Asset Management LLC’s holdings, making the stock its 16th largest position. Deltec Asset Management LLC’s holdings in Abbott Laboratories were worth $7,744,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently made changes to their positions in ABT. Sanders Morris Harris LLC increased its stake in Abbott Laboratories by 0.3% during the second quarter. Sanders Morris Harris LLC now owns 4,986 shares of the healthcare product maker’s stock worth $242,000 after acquiring an additional 16 shares during the last quarter. Janney Capital Management LLC increased its stake in Abbott Laboratories by 0.4% during the first quarter. Janney Capital Management LLC now owns 6,229 shares of the healthcare product maker’s stock worth $276,000 after acquiring an additional 26 shares during the last quarter. Alpha Windward LLC increased its stake in Abbott Laboratories by 0.6% during the second quarter. Alpha Windward LLC now owns 5,434 shares of the healthcare product maker’s stock worth $264,000 after acquiring an additional 30 shares during the last quarter. Johanson Financial Advisors Inc. increased its stake in Abbott Laboratories by 0.5% during the second quarter. Johanson Financial Advisors Inc. now owns 7,017 shares of the healthcare product maker’s stock worth $343,000 after acquiring an additional 37 shares during the last quarter. Finally, Country Club Trust Company n.a. increased its stake in Abbott Laboratories by 0.5% during the second quarter. Country Club Trust Company n.a. now owns 7,320 shares of the healthcare product maker’s stock worth $356,000 after acquiring an additional 38 shares during the last quarter. Hedge funds and other institutional investors own 71.50% of the company’s stock.

Abbott Laboratories (NYSE:ABT) opened at 52.51 on Friday. The firm has a market capitalization of $91.23 billion, a PE ratio of 73.54 and a beta of 1.06. The company’s 50-day moving average price is $50.14 and its 200 day moving average price is $47.04. Abbott Laboratories has a 1-year low of $37.38 and a 1-year high of $52.60.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, July 20th. The healthcare product maker reported $0.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.60 by $0.02. Abbott Laboratories had a return on equity of 14.43% and a net margin of 4.96%. The firm had revenue of $6.64 billion during the quarter, compared to the consensus estimate of $6.63 billion. During the same period in the prior year, the firm earned $0.55 EPS. The firm’s quarterly revenue was up 24.5% compared to the same quarter last year. On average, equities analysts anticipate that Abbott Laboratories will post $2.49 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, November 15th. Investors of record on Friday, October 13th will be issued a $0.265 dividend. The ex-dividend date of this dividend is Thursday, October 12th. This represents a $1.06 annualized dividend and a yield of 2.02%. Abbott Laboratories’s dividend payout ratio is currently 149.30%.

In related news, insider Brian J. Blaser sold 15,000 shares of the stock in a transaction on Thursday, July 27th. The stock was sold at an average price of $50.00, for a total value of $750,000.00. Following the completion of the sale, the insider now directly owns 143,154 shares in the company, valued at approximately $7,157,700. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Hubert L. Allen sold 4,600 shares of the firm’s stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $50.79, for a total value of $233,634.00. Following the sale, the insider now owns 105,479 shares of the company’s stock, valued at $5,357,278.41. The disclosure for this sale can be found here. Over the last quarter, insiders sold 218,150 shares of company stock valued at $10,811,179. 0.76% of the stock is owned by insiders.

WARNING: “Deltec Asset Management LLC Sells 400 Shares of Abbott Laboratories (NYSE:ABT)” was originally reported by BBNS and is the sole property of of BBNS. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://baseballnewssource.com/markets/deltec-asset-management-llc-trims-holdings-in-abbott-laboratories-abt/1605301.html.

Several research firms have issued reports on ABT. Citigroup Inc. began coverage on Abbott Laboratories in a research note on Thursday, August 17th. They set a “neutral” rating and a $53.00 target price for the company. Jefferies Group LLC reissued a “buy” rating and set a $55.00 target price on shares of Abbott Laboratories in a research note on Friday, June 16th. Zacks Investment Research raised Abbott Laboratories from a “hold” rating to a “buy” rating and set a $58.00 target price for the company in a research note on Friday. BTIG Research began coverage on Abbott Laboratories in a research note on Wednesday, June 21st. They set a “buy” rating and a $56.00 target price for the company. Finally, BidaskClub raised Abbott Laboratories from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 17th. Six equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $52.71.

Abbott Laboratories Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with our FREE daily email newsletter.

 


Latest News

American League Once Again Dominates National League
American League Once Again Dominates National League
Los Angeles Dodgers Waiting But Magic Number Down to One
Los Angeles Dodgers Waiting But Magic Number Down to One
Young Girl Hit by Foul Ball Rushed to Hospital
Young Girl Hit by Foul Ball Rushed to Hospital
New Home Run Record Reached in Major League Baseball
New Home Run Record Reached in Major League Baseball
Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?
Cleveland Indians Winning Streak Snapped at 22
Cleveland Indians Winning Streak Snapped at 22


Leave a Reply

 
© 2006-2017 BBNS.